Free Trial

IMAC (IMAC) Competitors

IMAC logo
$0.03 0.00 (-1.58%)
As of 05/21/2025

IMAC vs. THAR, CERO, WINT, EYEN, SNPX, ARTL, AXDX, MTNB, NBY, and CTCX

Should you be buying IMAC stock or one of its competitors? The main competitors of IMAC include Tharimmune (THAR), CERo Therapeutics (CERO), Windtree Therapeutics (WINT), Eyenovia (EYEN), Synaptogenix (SNPX), Artelo Biosciences (ARTL), Accelerate Diagnostics (AXDX), Matinas Biopharma (MTNB), NovaBay Pharmaceuticals (NBY), and Carmell (CTCX). These companies are all part of the "medical" sector.

IMAC vs.

IMAC (NASDAQ:IMAC) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership, community ranking and media sentiment.

Tharimmune has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat Tharimmune's return on equity.

Company Net Margins Return on Equity Return on Assets
IMAC-75.40% -52.17% -34.51%
Tharimmune N/A -167.63%-130.18%

IMAC received 69 more outperform votes than Tharimmune when rated by MarketBeat users. However, 100.00% of users gave Tharimmune an outperform vote while only 60.17% of users gave IMAC an outperform vote.

CompanyUnderperformOutperform
IMACOutperform Votes
71
60.17%
Underperform Votes
47
39.83%
TharimmuneOutperform Votes
2
100.00%
Underperform Votes
No Votes

Tharimmune has lower revenue, but higher earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$15.22M0.05-$10.54MN/AN/A
TharimmuneN/AN/A-$9.32M-$7.88-0.17

Tharimmune has a consensus price target of $17.00, indicating a potential upside of 1,140.88%. Given Tharimmune's stronger consensus rating and higher possible upside, analysts plainly believe Tharimmune is more favorable than IMAC.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IMAC
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Tharimmune
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50

In the previous week, IMAC had 4 more articles in the media than Tharimmune. MarketBeat recorded 4 mentions for IMAC and 0 mentions for Tharimmune. Tharimmune's average media sentiment score of 0.00 beat IMAC's score of -0.26 indicating that Tharimmune is being referred to more favorably in the news media.

Company Overall Sentiment
IMAC Neutral
Tharimmune Neutral

IMAC has a beta of -0.88, indicating that its stock price is 188% less volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.

24.3% of IMAC shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 10.0% of IMAC shares are held by company insiders. Comparatively, 10.0% of Tharimmune shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Tharimmune beats IMAC on 10 of the 16 factors compared between the two stocks.

Get IMAC News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMAC vs. The Competition

MetricIMACSpecialty Outpatient Clinics IndustryMedical SectorNASDAQ Exchange
Market Cap$824,000.00$814,500.00$5.33B$8.39B
Dividend YieldN/AN/A5.21%4.11%
P/E RatioN/AN/A26.7119.71
Price / Sales0.050.05386.13120.55
Price / CashN/AN/A38.2534.62
Price / Book0.050.056.774.50
Net Income-$10.54M-$10.54M$3.23B$248.22M
7 Day PerformanceN/AN/A1.80%0.56%
1 Month PerformanceN/AN/A11.10%13.17%
1 Year PerformanceN/AN/A17.11%7.30%

IMAC Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMAC
IMAC
N/A$0.03
-1.6%
N/A-99.0%$824,000.00$15.22M0.00106
THAR
Tharimmune
1.5371 of 5 stars
$1.56
+3.3%
$17.00
+989.7%
-77.0%$3.34MN/A-0.162Gap Down
CERO
CERo Therapeutics
3.072 of 5 stars
$0.62
-4.9%
$11.00
+1,679.9%
-99.5%$3.33MN/A0.008Earnings Report
Analyst Forecast
WINT
Windtree Therapeutics
2.2931 of 5 stars
$0.91
+6.7%
$350.00
+38,386.9%
-99.6%$3.32MN/A-0.0630Earnings Report
Gap Down
EYEN
Eyenovia
0.9254 of 5 stars
$1.17
+8.4%
$2.00
+70.8%
-97.6%$3.31M$57,336.00-0.0240News Coverage
Earnings Report
Gap Down
SNPX
Synaptogenix
2.177 of 5 stars
$2.38
-1.2%
$14.00
+488.0%
-54.2%$3.31MN/A-0.234Positive News
Earnings Report
Gap Up
ARTL
Artelo Biosciences
2.33 of 5 stars
$1.00
-2.0%
$5.50
+450.0%
-36.9%$3.28MN/A-0.355Negative News
Gap Up
AXDX
Accelerate Diagnostics
1.7325 of 5 stars
$0.13
-12.2%
N/AN/A$3.28M$11.70M-0.05220Analyst Forecast
Gap Down
High Trading Volume
MTNB
Matinas Biopharma
N/A$0.63
-10.5%
N/AN/A$3.21M$1.10M-0.1330Gap Down
NBY
NovaBay Pharmaceuticals
1.9366 of 5 stars
$0.55
-2.5%
$0.85
+54.5%
-87.8%$3.20M$9.78M-0.0130News Coverage
Analyst Forecast
CTCX
Carmell
N/A$0.15
-1.3%
N/A+35.8%$3.20M$32,839.000.0014Gap Up

Related Companies and Tools


This page (NASDAQ:IMAC) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners